Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Rexahn Pharmaceuticals Announces New President, CFO | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Rexahn Pharmaceuticals Announces New President, CFO

Mr. Swirsky joins the company from his position of CEO at GenVec

By: Betsy Louda

, Contract Pharma

Rexahn Pharmaceuticals has announced the appointment of Douglas J. Swirsky as its president and chief financial officer. 

 

Mr. Swirsky was most recently president, chief executive officer, and a director of GenVec, Inc., a publicly-traded biotechnology company. He is on the board of directors of Fibrocell Science, Inc., Cellectar Biosciences, Inc., and Pernix Therapeutics Holdings, Inc.  

 

“Doug’s extensive leadership, corporate finance and strategy experience make him a strong addition to the Rexahn team,” said Dr. Peter Suzdak, chief executive officer for Rexahn Pharmaceuticals.  “We look forward to Doug’s contributions as we progress our clinical programs through proof of concept studies to later stage clinical development.”  

 

Mr. Swirsky replaces Dr. Tae Heum “Ted” Jeong, sr. vice president of Finance, chief financial officer, and secretary, who informed the Company of his resignation in December to pursue another opportunity.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters